Thyroid Replacement (T4) ICD-10 / CPT Cheat Sheet

Why This Cheat Sheet Exists

Coding errors for thyroid therapy are common, and they disproportionately affect women. Hypothyroidism affects approximately 5% of the U.S. Population, and women are diagnosed at a rate roughly five to eight times higher than men. Autoimmune thyroid disease, including Hashimoto's thyroiditis, is the leading cause of hypothyroidism in iodine-sufficient countries and carries its own specific codes that reveal more accurate clinical documentation and sometimes different coverage pathways.

Getting the right code also tells your clinician's story. A woman on levothyroxine during pregnancy is not the same as a woman on levothyroxine for subclinical hypothyroidism in perimenopause, and the codes should reflect that difference.

This reference covers the ICD-10-CM diagnosis codes and CPT procedure codes you will encounter most often when managing T4 replacement therapy in women across reproductive years, pregnancy, postpartum, perimenopause, and post-menopause.

ICD-10-CM Diagnosis Codes for Hypothyroidism and Related Conditions

The correct diagnosis code depends on the cause and clinical context of hypothyroidism, not just the TSH result.

Primary Hypothyroidism Codes

| ICD-10-CM Code | Description | When to Use | |---|---|---| | E03.9 | Hypothyroidism, unspecified | Use when cause is undocumented or unclear | | E06.3 | Autoimmune thyroiditis (Hashimoto's) | Positive TPO antibodies, goiter, confirmed autoimmune etiology | | E03.0 | Congenital hypothyroidism with diffuse goiter | Congenital cases with structural involvement | | E03.1 | Congenital hypothyroidism without goiter | Neonatal screening positive, no structural finding | | E03.2 | Hypothyroidism due to medicaments and exogenous substances | Amiodarone, lithium, or interferon-induced | | E03.3 | Postinfectious hypothyroidism | Subacute thyroiditis sequela | | E03.4 | Atrophy of thyroid | End-stage Hashimoto's, post-ablation atrophy | | E03.8 | Other specified hypothyroidism | Iodine-deficiency related, iatrogenic (non-drug) | | E02 | Subclinical iodine-deficiency hypothyroidism | Rarely used in U.S. Practice; endemic goiter regions | | E89.0 | Postprocedural hypothyroidism | After thyroidectomy or radioactive iodine ablation |

For most women with Hashimoto's thyroiditis, E06.3 is the more precise code and better reflects the autoimmune burden she carries. Payers increasingly accept E06.3 as sufficient to justify TSH plus TPO antibody testing in the initial workup.

Women-Specific and Life-Stage Codes

These codes are essential for accurate documentation in women's health contexts and are frequently undercoded in practice.

| ICD-10-CM Code | Description | Life Stage | |---|---|---| | O99.280 | Hypothyroidism complicating pregnancy, unspecified trimester | Pregnancy | | O99.281 | Hypothyroidism complicating pregnancy, first trimester | Pregnancy | | O99.282 | Hypothyroidism complicating pregnancy, second trimester | Pregnancy | | O99.283 | Hypothyroidism complicating pregnancy, third trimester | Pregnancy | | O90.5 | Postpartum thyroiditis | Postpartum | | E06.3 | Autoimmune thyroiditis | Any stage; especially reproductive years | | N91.2 | Amenorrhea, unspecified | When hypothyroidism drives menstrual disruption | | E28.2 | Polycystic ovary syndrome | Code alongside thyroid code in PCOS with hypothyroidism | | E66.09 | Other obesity due to excess calories | When hypothyroidism contributes to metabolic picture |

Postpartum thyroiditis affects approximately 5 to 10% of women in the year following delivery and is frequently missed. It progresses through a hyperthyroid phase followed by a hypothyroid phase, with up to 30% of affected women developing permanent hypothyroidism requiring long-term levothyroxine. O90.5 should be coded during the active postpartum period; once the condition becomes chronic, transition to E03.9 or E06.3 as appropriate.

Subclinical Hypothyroidism

Subclinical hypothyroidism (TSH elevated, free T4 normal) has its own coding consideration. ICD-10-CM does not have a dedicated "subclinical hypothyroidism" code. Current clinical practice typically uses E03.9 with documentation in the note specifying the subclinical nature. Some practices use R79.89 (other specified abnormal findings of blood chemistry) when the decision is observation rather than treatment, though E03.9 remains the most common choice when treatment is initiated.

CPT Procedure Codes for Thyroid Monitoring

Laboratory CPT Codes

The laboratory codes for thyroid monitoring are straightforward but are frequently ordered in combinations that payers scrutinize. Knowing which panels are supported by which diagnoses saves your patient a denial.

| CPT Code | Test | Typical Frequency | Supported By | |---|---|---|---| | 84443 | TSH (thyroid-stimulating hormone) | Every 6-12 months when stable; every 4-6 weeks when adjusting | E03.9, E06.3, O99.28x | | 84439 | Free T4 (FT4) | At baseline; with TSH if pituitary disease suspected | E03.9, E06.3 | | 84436 | Total T4 | Less commonly ordered; useful in pregnancy for interpretation | O99.28x | | 86376 | TPO antibodies (anti-thyroid peroxidase) | Once, at diagnosis | E06.3 | | 86200 | Anti-thyroglobulin antibodies | Once, at diagnosis or if TPO negative | E06.3 | | 84432 | Thyroglobulin | Post-thyroid cancer surveillance, not routine hypothyroidism | C73 | | 84479 | T3 uptake | Rarely used; indirect measure, largely replaced by free T4 | E03.9 | | 84481 | Free T3 | Ordered selectively in persistent symptoms despite normal TSH/FT4 | E03.9 |

The American Thyroid Association's 2017 guidelines recommend checking TSH every 4 to 6 weeks during dose adjustments, and every 6 to 12 months once a patient is stable on a consistent dose. Payers typically support this frequency without prior authorization.

In pregnancy, TSH monitoring intensifies. The Endocrine Society recommends TSH measurement every 4 weeks during the first half of pregnancy and at least once between 26 and 32 weeks. Each measurement during pregnancy should use the trimester-specific reference range rather than the standard non-pregnant range.

Office Visit and E/M CPT Codes

| CPT Code | Description | Typical Use | |---|---|---| | 99213 | Established patient office visit, moderate complexity | Stable hypothyroidism, routine TSH check visit | | 99214 | Established patient office visit, moderate-high complexity | Dose adjustment, new pregnancy, symptom review | | 99215 | Established patient office visit, high complexity | Multiple comorbidities, complex medication management | | 99202-99205 | New patient office visit (level 2-5) | Initial hypothyroidism evaluation | | 99242-99244 | Office consultation (where payers accept) | Endocrinology referral for complex cases |

Since the 2021 E/M revisions, office visit coding is now driven by medical decision-making (MDM) complexity, not purely by time documentation. A levothyroxine dose adjustment in a pregnant woman with Hashimoto's thyroiditis and PCOS would typically support 99214 based on moderate MDM, given the number of diagnoses being managed and the prescription drug management involved.

Telehealth and Remote Monitoring CPT Codes

Women using telehealth platforms for thyroid management should be aware of these codes, which have expanded significantly since 2020.

| CPT Code | Description | |---|---| | 99441-99443 | Telephone evaluation and management (non-video) | | 99421-99423 | Online digital E/M (patient-initiated, asynchronous) | | 99454 | Remote physiologic monitoring, device supply | | G2012 | Brief virtual check-in (5-10 minutes, established patient) |

Levothyroxine Prescribing: Dose and Drug Codes

NDC Considerations and Common Formulations

Levothyroxine is available as a branded product (Synthroid, Tirosint, Unithroid, Levoxyl) and as generics. FDA bioequivalence standards require that all approved formulations fall within an 80 to 125% bioavailability range relative to the reference product, but the American Thyroid Association recommends that patients remain on the same brand or manufacturer once stable, because even small formulation changes can shift TSH by a clinically meaningful margin in sensitive patients. This is particularly relevant for women in pregnancy, where TSH targets are tight.

Tirosint (levothyroxine soft gel capsule) and Tirosint-SOL (liquid formulation) contain no dyes, lactose, or gluten and may be preferred in women with inflammatory bowel disease, celiac disease, or known lactose intolerance, all of which reduce T4 absorption from standard tablets.

Typical Starting Doses by Life Stage

Dosing is weight-based as a starting point but must be individualized. The general starting dose for complete hypothyroidism is 1.6 mcg/kg/day, but women require adjustment across life stages.

| Life Stage | Typical Approach | TSH Target | |---|---|---| | Reproductive years (euthyroid baseline) | 1.6 mcg/kg/day; adjust by TSH | 0.5 to 4.5 mIU/L | | Trying to conceive | Optimize TSH before conception; many endocrinologists target <2.5 mIU/L pre-conception | <2.5 mIU/L | | First trimester of pregnancy | Increase dose 25-30% immediately on confirmed pregnancy | 0.1 to 2.5 mIU/L | | Second and third trimester | Continue adjusted dose; recheck every 4 weeks | 0.2 to 3.0 mIU/L | | Postpartum | Return to pre-pregnancy dose; recheck TSH at 6 weeks postpartum | 0.5 to 4.5 mIU/L | | Perimenopause | Monitor TSH; estrogen fluctuations may alter thyroid-binding globulin and apparent T4 levels | 0.5 to 4.5 mIU/L | | Post-menopause on oral estrogen | Oral estrogen raises TBG; may need dose increase | 0.5 to 4.5 mIU/L |

Women on oral estrogen therapy, including combined oral contraceptives or oral menopausal hormone therapy, may need a higher levothyroxine dose because estrogen raises thyroid-binding globulin (TBG), reducing free T4. Transdermal estrogen does not significantly raise TBG and is therefore less likely to affect levothyroxine requirements. This is a clinically meaningful sex-specific pharmacokinetic interaction that is rarely discussed but directly affects dosing.

Pregnancy and Lactation Safety

Levothyroxine is not contraindicated in pregnancy. It is required in pregnancy for women with hypothyroidism. Untreated or undertreated hypothyroidism during pregnancy carries serious risks for both mother and fetus.

Pregnancy

Levothyroxine is FDA Pregnancy Category A, which means adequate and well-controlled human studies have not shown a risk to the fetus. T4 crosses the placenta in limited amounts and is essential for fetal neurodevelopment, particularly in the first trimester before the fetal thyroid becomes functional around week 10 to 12.

The Controlled Antenatal Thyroid Screening (CATS) trial published in the NEJM found that universal screening and treatment for subclinical hypothyroidism in pregnancy did not improve cognitive outcomes in offspring at age 3, but this trial has been critiqued for late treatment initiation (median gestational age at treatment start was 13.3 weeks). The neurodevelopmental window most sensitive to thyroid hormone is earlier. Current Endocrine Society guidelines still recommend treating overt hypothyroidism and most cases of subclinical hypothyroidism in pregnancy, especially with TPO antibody positivity.

Dose increase protocol: Once pregnancy is confirmed, women with known hypothyroidism should increase their levothyroxine dose by approximately 25 to 30% immediately, typically achieved by taking two extra doses per week, then confirm with TSH at 4 weeks. This approach is recommended by the Endocrine Society and avoids the delay of waiting for a TSH result before acting.

Hypothyroidism in pregnancy is associated with increased risk of miscarriage, preeclampsia, placental abruption, preterm birth, and low birth weight. These risks are substantially reduced with adequate T4 replacement and TSH within trimester-specific targets.

Lactation

Levothyroxine transfers into breast milk in very small amounts. The amount transferred is insufficient to cause harm to the infant and is also insufficient to treat congenital hypothyroidism in a breastfed newborn. Women with hypothyroidism should continue levothyroxine while breastfeeding without interruption. LactMed (NLM) classifies levothyroxine as compatible with breastfeeding.

Contraception Requirement

Levothyroxine itself carries no teratogenic risk and does not require contraception. The contraception planning consideration is the reverse: women with hypothyroidism who become pregnant inadvertently and whose TSH is not optimized before conception have a higher rate of early pregnancy loss. If you are on levothyroxine and planning pregnancy, have your TSH checked and optimized before stopping contraception.

Thyroid Conditions Specific to Women: PCOS, Perimenopause, and Hair Loss

PCOS and Thyroid Disease

Women with PCOS have a higher prevalence of Hashimoto's thyroiditis than the general population. A 2018 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that TPO antibody positivity was significantly more common in women with PCOS. When both conditions coexist, the recommended coding approach is to list E28.2 (PCOS) and E06.3 (Hashimoto's) as separate diagnoses. Subclinical hypothyroidism can worsen insulin resistance and anovulation in PCOS, so optimizing TSH may improve menstrual regularity and ovulatory function even at TSH levels some clinicians would otherwise observe.

Perimenopause and Thyroid Overlap

Perimenopause and hypothyroidism share overlapping symptoms: fatigue, weight changes, mood shifts, irregular periods, cognitive fog, and sleep disturbance. This creates a genuine clinical challenge. A 2021 review in Menopause noted that thyroid dysfunction is more common in women aged 45 to 65 and that untreated hypothyroidism may amplify vasomotor symptoms. The practical implication: every woman presenting with perimenopausal symptoms should have TSH checked before attributing all symptoms to estrogen decline. Code both conditions separately if both are present.

A practical three-code framework for perimenopausal women with hypothyroidism and symptoms:

1. N95.1 (Menopausal and female climacteric states) for vasomotor and perimenopausal symptoms
2. E06.3 or E03.9 for the thyroid diagnosis
3. Z79.890 (Hormone replacement therapy) if the patient is on menopausal HT concurrently

This three-code structure ensures accurate documentation of the clinical complexity and supports the level of E/M coding (99214 or 99215) that the visit genuinely warrants.

Female Pattern Hair Loss and Thyroid

Hair loss is one of the most distressing symptoms of hypothyroidism for women. ICD-10-CM L66.1 or L65.9 may be appropriate secondary codes when hair loss is the presenting complaint prompting thyroid evaluation. Once levothyroxine is optimized, hair regrowth may take three to six months and is not always complete, particularly if androgenetic alopecia coexists.

Evidence Gaps: What We Know and Do Not Know in Women

Women have been enrolled in thyroid trials at higher absolute numbers than men simply because they are the majority of patients, but sex-disaggregated outcome data and female-specific dosing studies are sparse.

Key gaps:

• Most levothyroxine pharmacokinetic studies used mixed-sex cohorts without reporting sex-stratified absorption or clearance data. We extrapolate weight-based dosing from studies that did not specifically model female body composition changes across the menstrual cycle.
• The effect of cyclical estrogen and progesterone fluctuations on TBG and free T4 levels across the menstrual cycle is not well characterized in levothyroxine-treated women.
• The CATS trial enrolled women with subclinical hypothyroidism in pregnancy but did not examine maternal quality of life, postpartum depression rates, or long-term metabolic outcomes as primary endpoints.
• Data on levothyroxine dosing in transgender women on feminizing hormone therapy are very limited. Estrogen-mediated TBG elevation would be expected to increase levothyroxine requirements, similar to what is seen with oral contraceptive use, but no prospective studies address this directly.

The Endocrine Society clinical practice guideline states: "The goal of treatment is to restore serum TSH to within the reference range, improve symptoms, and prevent the adverse consequences of untreated hypothyroidism." That goal, stated clearly, does not yet have a female-specific refinement for optimal TSH sub-targets outside of pregnancy.

Who This Coding Framework Applies To / Who Should Refer

Women Who Fit Standard T4 Replacement Coding

• Women with confirmed primary hypothyroidism managed in primary care or OB-GYN settings
• Women on stable levothyroxine doses with no complicating conditions
• Women in pregnancy with known hypothyroidism being monitored per Endocrine Society intervals
• Postpartum women transitioning from pregnancy dosing back to baseline

Women Who Need Endocrinology Co-Management (and More Complex Coding)

• Women with central (pituitary) hypothyroidism: TSH is unreliable as the primary monitoring tool; free T4 drives management. Code E23.0 (Hypopituitarism) plus E03.8.
• Women post-thyroidectomy for thyroid cancer requiring TSH suppression (target TSH <0.1 mIU/L): Use C73 (Malignant neoplasm of thyroid) plus Z85.850 (Personal history of malignant neoplasm of thyroid).
• Women with persistent symptoms on levothyroxine monotherapy who may be candidates for combination T4/T3 therapy. Code remains E03.9 or E06.3; the clinical discussion is whether to add liothyronine (T3).
• Women with very high TPO antibody titers and symptoms suggesting progression of Hashimoto's to overt hypothyroidism faster than expected.

Quick Reference Summary Table

| Scenario | Primary ICD-10 | Secondary ICD-10 | Key CPT Codes | |---|---|---|---| | Primary hypothyroidism, stable | E03.9 | - | 99213, 84443 | | Hashimoto's thyroiditis | E06.3 | - | 99213, 84443, 86376 | | Subclinical hypothyroidism | E03.9 | - | 99214, 84443, 84439 | | Hypothyroidism in pregnancy, first trimester | O99.281 | E06.3 | 99214, 84443, 84439 | | Postpartum thyroiditis | O90.5 | - | 99213, 84443, 84439 | | PCOS with Hashimoto's | E28.2 | E06.3 | 99214, 84443, 86376 | | Post-thyroidectomy hypothyroidism | E89.0 | Z85.850 | 99214, 84443, 84432 | | Perimenopause with hypothyroidism | E06.3 | N95.1 | 99214, 84443 | | Drug-induced hypothyroidism | E03.2 | - | 99214, 84443 | | Central hypothyroidism | E23.0 | E03.8 | 99215, 84439 |